• If you are wondering whether GE HealthCare Technologies' current share price offers value, it helps to start by looking at how the stock has actually been trading and how that lines up with its fundamentals.
• The stock last closed at US$64.51, with returns of 1.1% over the past week and 3.6% over the past month, while being down 22.1% year to date and 11.6% over the past year.
• Recent news coverage has focused on GE HealthCare Technologies as a standalone medical equipment company and how investors are assessing its prospects in imaging, diagnostics and related services. Commentators have also pointed to changing sentiment around healthcare spending and capital investment, which helps frame the recent share price moves.
• On Simply Wall St's checks, GE HealthCare Technologies scores a full 6 out of 6 on valuation. The next step is to compare what different valuation methods say about the stock today and then look at an even deeper way to think about value at the end of this article.

Approach 1: GE HealthCare Technologies Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a stock could be worth by projecting the company’s future cash flows and then discounting them back to today’s value using a required rate of return.

For GE HealthCare Technologies, the model uses a 2 Stage Free Cash Flow to Equity approach, starting from last twelve months free cash flow of about US$1.57b. Analyst estimates feed into the near term projections, then Simply Wall St extrapolates further out, with projected free cash flow of about US$2.18b in 2028 and a series of annual projections through 2035. These future cash flows are converted into today’s dollars using discount factors, which are then summed to get an equity value per share.

On this basis, the DCF model points to an estimated intrinsic value of about US$106.23 per share. Compared with the recent share price of US$64.51, this implies the stock screens as around 39.3% undervalued on this cash flow view.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests GE HealthCare Technologies is undervalued by 39.3%. Track this in your watchlist or portfolio, or discover 46 more high quality undervalued stocks.

Approach 2: GE HealthCare Technologies Price vs Earnings

For a profitable business, the P/E ratio is a useful way to think about value because it links what you pay for each share to the earnings the company is currently generating. Higher growth expectations or lower perceived risk often justify a higher P/E, while slower expected growth or higher risk usually point to a lower, more cautious multiple.

GE HealthCare Technologies currently trades on a P/E of about 15.37x. That sits below the Medical Equipment industry average P/E of about 24.81x and the peer group average of roughly 25.00x. Simply Wall St also calculates a “Fair Ratio” of around 25.15x for GE HealthCare Technologies. This is the P/E level that might be expected given factors such as its earnings profile, industry, profit margins, market cap and risk characteristics.

The Fair Ratio is more tailored than a simple peer or industry comparison because it adjusts for company specific features rather than assuming all stocks in the same sector deserve similar multiples. Comparing the Fair Ratio of 25.15x with the current P/E of 15.37x suggests GE HealthCare Technologies trades below the level implied by these fundamentals on this metric.

Result: UNDERVALUED

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Upgrade Your Decision Making: Choose your GE HealthCare Technologies Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives are introduced here as simple stories you build about GE HealthCare Technologies that link your views on its future revenue, earnings and margins to a financial forecast, a Fair Value, and then a clear comparison with today’s share price. All of this is done within the Narratives tool on Simply Wall St’s Community page, where investors can, for example, anchor on the more optimistic Fair Value around US$98 or a more cautious view near US$65, see how those different stories respond when new news or earnings arrive, and then decide for themselves how the current price stacks up against the Fair Value that best fits their own expectations for the company.

Do you think there's more to the story for GE HealthCare Technologies? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.